Si-Bone Inc Cash Flow Conversion Efficiency
Si-Bone Inc cash flow conversion efficiency. Based on the latest financial reports, Si-Bone Inc (SIBN) has a cash flow conversion efficiency ratio of 0.004x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($777.00K) by net assets ($182.35 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Si-Bone Inc (2013–2025)
Cash flow conversion efficiency of Si-Bone Inc from 2013 to 2025. This chart illustrates how Si-Bone Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View SIBN stock price for real-time trading data and today's change.
Si-Bone Inc Cash Flow Conversion Ratio Explained
Si-Bone Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Si-Bone Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Si-Bone Inc ranked by their cash flow conversion efficiency. Also see market cap of Si-Bone Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
China West Construction Group Co Ltd
SHE:002302
|
-0.013x |
|
Guangdong Shaoneng Group Co Ltd
SHE:000601
|
0.095x |
|
Kri-Kri Milk Industry S.A
AT:KRI
|
0.059x |
|
Festi hf
IC:FESTI
|
-0.001x |
|
Dashang Co Ltd
SHG:600694
|
0.006x |
|
SUFA Technology Industry Co Ltd CNNC
SHE:000777
|
0.002x |
|
SpyGlass Pharma, Inc.
NASDAQ:SGP
|
-0.064x |
|
Logwin AG
XETRA:TGHN
|
0.123x |
Annual Cash Flow Conversion Efficiency for Si-Bone Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of Si-Bone Inc from 2013 to 2025. Review SIBN free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $177.53 Million | $-675.00K | -0.004x | +94.89% |
| 2024-12-31 | $166.96 Million | $-12.43 Million | -0.074x | +32.64% |
| 2023-12-31 | $169.38 Million | $-18.71 Million | -0.110x | +73.93% |
| 2022-12-31 | $98.30 Million | $-41.66 Million | -0.424x | -44.08% |
| 2021-12-31 | $134.42 Million | $-39.53 Million | -0.294x | -62.45% |
| 2020-12-31 | $169.36 Million | $-30.66 Million | -0.181x | +63.93% |
| 2019-12-31 | $63.01 Million | $-31.63 Million | -0.502x | -211.81% |
| 2018-12-31 | $90.19 Million | $-14.52 Million | -0.161x | -218.81% |
| 2017-12-31 | $-129.38 Million | $-17.53 Million | 0.135x | -12.06% |
| 2016-12-31 | $-108.73 Million | $-16.75 Million | 0.154x | +101.86% |
| 2015-12-31 | $3.23 Million | $-26.72 Million | -8.264x | -116.34% |
| 2014-12-31 | $6.89 Million | $-26.33 Million | -3.820x | -1215.61% |
| 2013-12-31 | $-1.65 Million | $-566.00K | 0.342x | -- |
About Si-Bone Inc
SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. The company also provides IFUSE, a triangular titanium … Read more